Rhythmic therapeutic exercise program for breast cancer survivors

Effectiveness of a rhythmic therapeutic-exercise program on cancer-related fatigue and quality of life of breast cancer women

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13777029

Enrollment

Registered

2023-01-13

Start date

2023-03-01

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue in breast cancer survivors Signs and Symptoms

Interventions

After the baseline assessment, participants will be randomly assigned to one of two groups: group A (intervention) or group B (control). The sample allocation will be carried out using the block rando

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Breast cancer disease-free women aged 45-60 years (meaning that they completed their oncology treatment 2 to 6 months before enrollment in the study), except if they are receiving hormonotherapy 2. Willing to be assigned to any of the two study intervention groups

Exclusion criteria

Exclusion criteria: 1. Cognitive impairments 2. Neurological disorders 3. Cardiovascular diseases or high blood pressure not controlled with medication 5. Surgery on lower limbs affecting gait within the previous 6 months 6. Medical or other musculoskeletal problems that could affect the ability to complete objective assessments or exercise with safety 7. Cancer recurrence

Design outcomes

Primary

Measure	Time frame
1. Cancer-related fatigue will be evaluated using the Greek version of the Multidimensional Fatigue Inventory (MFI-Greek version) and the Greek version of the Modified Fatigue Impact Scale (MFIS) at baseline, 8, and 16 weeks 2. Functional mobility will be assessed using the Timed Up and Go Test at baseline, 8, and 16 weeks 3. Physical activity will be assessed using 6 minutes walking test (6MWS) at baseline, 8, and 16 weeks 4. Quality of life will be evaluated using the Greek version of the SF-36 Scale at baseline, 8, and 16 weeks	—

Measure

Time frame

1. Cancer-related fatigue will be evaluated using the Greek version of the Multidimensional Fatigue Inventory (MFI-Greek version) and the Greek version of the Modified Fatigue Impact Scale (MFIS) at baseline, 8, and 16 weeks 2. Functional mobility will be assessed using the Timed Up and Go Test at baseline, 8, and 16 weeks 3. Physical activity will be assessed using 6 minutes walking test (6MWS) at baseline, 8, and 16 weeks 4. Quality of life will be evaluated using the Greek version of the SF-36 Scale at baseline, 8, and 16 weeks

—

Secondary

Measure	Time frame
1. Grip strength will be assessed using a hand dynamometer at baseline, 8, and 16 weeks 2. Lower limbs’ muscle strength will be assessed using the 30-sec sit-to-stand test at baseline, 8, and 16 weeks 3. Balance will be assessed using the Functional Reach Test at baseline, 8, and 16 weeks 4. Depression and anxiety will be assessed using the Greek version of the Depression, Anxiety and Stress Scale-21 (DASS-21) at baseline, 8, and 16 weeks	—

Measure

Time frame

1. Grip strength will be assessed using a hand dynamometer at baseline, 8, and 16 weeks 2. Lower limbs’ muscle strength will be assessed using the 30-sec sit-to-stand test at baseline, 8, and 16 weeks 3. Balance will be assessed using the Functional Reach Test at baseline, 8, and 16 weeks 4. Depression and anxiety will be assessed using the Greek version of the Depression, Anxiety and Stress Scale-21 (DASS-21) at baseline, 8, and 16 weeks

—

Countries

Greece

Contacts

Public ContactEvaggelos Fillopoulos

dioikisi@cancerhellas.org+30 (0)6936552255

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026